Here are 1-2 brief analogies to describe OSR Health (OSRH) to someone unfamiliar with it:

• They're like ARM Holdings, but for cutting-edge R&D platforms in the biotherapeutics sector.
• Think of them as the Intel Inside for drug discovery and clinical trials, providing essential underlying technologies rather than the final drugs.

• Proprietary Platform Technologies: Advanced technological solutions developed for enhancing the efficiency of clinical trial programs.
• Technology Licensing and Marketing: The service of partnering with biotherapeutics companies to license and commercialize OSRH's platform technologies for drug R&D.

Based on the provided company description, OSR Health (OSRH) primarily sells to other companies. The description does not list specific names of its major customer companies or their symbols. Instead, it details the categories of companies it partners with and targets:

• Biotherapeutics companies: OSRH partners with biotherapeutics companies that possess innovative and proprietary drug R&D "platform technologies" for broad application to efficient clinical trial programs.
• US and EU biotech companies: OSRH focuses on value creation through investments and collaborations with US and EU biotech companies, with a strategic goal of expansion into South Korea and generally into Asia.

Kuk Hyoun Hwang Chief Executive Officer

Kuk Hyoun Hwang, also known as Peter Hwang, was appointed as CEO in February 2025. He is leading a strategic review of a potential combination of OSR Health's medical device subsidiaries, Woori IO and RMC, with the goal of forming an integrated medical technology and distribution company.

Gihyoun Bang Chief Financial Officer

Gihyoun Bang, also known as Chris Bang, serves as the Chief Financial Officer.

Dr. Constance Höfer Chief Scientific Officer

Dr. Constance Höfer was appointed Chief Scientific Officer in March 2025. She brings over two decades of experience in drug development, particularly in oncology and immunology. Prior to joining OSR Health, Dr. Höfer led global programs at Merck Healthcare, spanning from preclinical to late-stage clinical development. She also held senior leadership positions at Sandoz Biopharmaceuticals, Priaxon AG, and Medigene AG, contributing to therapeutic programs across various modalities. Dr. Höfer holds a PhD in Pharmacology from the University of Newcastle.

Yeiseok Kim Chief Operating Officer

Yeiseok Kim was appointed Chief Operating Officer, effective April 16, 2026. He is a licensed physician and has been supporting OSR Health's cross-border healthcare investments and pharmaceutical licensing activities since 2020.

Jun Whang Chief Legal Officer

Jun Whang, also a Director, commenced his role in 2020.

The key risks for OSR Health (OSRH) primarily stem from its financial stability, the inherent uncertainties of biotechnology development, and its reliance on strategic partnerships and intellectual property protection.

1. Financial Stability and Going Concern Risks: OSR Health faces significant financial challenges, including unprofitability and a limited cash runway. The company has reported a net loss and is not forecasted to become profitable in the near term, with less than one year of cash runway based on its free cash flow trend. Shareholder dilution has also been substantial, with a significant increase in shares outstanding over the past year. Furthermore, OSR Health received a NASDAQ delisting warning due to its share price falling below the minimum bid requirement, necessitating it to maintain a certain share price by March 2026 to avoid delisting. These financial pressures pose an immediate and existential threat to the company's operations and its ability to fund ongoing development and expansion initiatives.
2. Uncertainty and Risks Associated with Biotechnology Development and Commercialization: OSR Health's business model revolves around developing and licensing proprietary platform technologies for clinical trial programs in areas like immuno-oncology and regenerative biologics. This field is characterized by inherent uncertainty, long development cycles, and high failure rates. Key risks include the potential for their early-stage development programs to fail in clinical trials, delays in regulatory approvals, or a lack of market acceptance for their platform technologies and pipeline products. The success of these technologies in ultimately addressing unmet medical needs is fundamental to OSR Health's commercial viability.
3. Dependence on Strategic Partnerships, Licensing Agreements, and Intellectual Property Protection: OSR Health explicitly leverages an international network of partners and relies on licensing its platform technologies. This strategy introduces risks related to the performance and reliability of these partners and the effective execution of licensing agreements, including the potential that anticipated milestones and revenues may not be fully realized. Furthermore, as a company focused on proprietary platform technologies, the inability to adequately protect its intellectual property (IP) from infringement or theft across its global operations would severely undermine its value and competitive position.

The emergence of comprehensive, integrated digital platforms for end-to-end clinical trial management and optimization, potentially offered by major pharmaceutical companies, large contract research organizations (CROs), or tech giants entering the healthcare sector. These platforms could combine drug R&D, trial design, patient recruitment, data collection, real-time analytics, and regulatory submission capabilities into a single, highly efficient ecosystem, directly challenging OSR Health's specialized model of marketing and licensing individual "proprietary platform technologies" for efficient clinical trial programs.

OSR Holdings (OSRH) operates in several key healthcare sectors, with addressable markets including:

• Drug R&D Platform Technologies and Clinical Trial Programs: The global drug discovery technology market, which encompasses innovative methodologies for drug development from laboratory to preclinical evaluation, was valued at USD 32.69 billion in 2025 and is projected to exceed USD 80.27 billion by 2035, demonstrating a compound annual growth rate (CAGR) of 9.4% from 2026 to 2035. Relatedly, the global AI clinical trial optimization market is anticipated to reach USD 1,494.6 million in 2026 and grow to USD 5,065.7 million by 2035, at a CAGR of 14.5%. The U.S. AI clinical trial optimization market alone is projected to reach USD 483.9 million in 2026 and USD 1,525.6 million by 2035. Europe's AI clinical trial optimization market is estimated at USD 432.8 million in 2026, with a forecast to reach USD 1,490.2 million by 2035. Additionally, the global clinical trial software market, which supports efficient data management and streamlined regulatory processes, was valued at approximately USD 1.03 billion in 2025 and is expected to grow to USD 3.23 billion by 2034, with a CAGR of 13.74% from 2025 to 2034. The global clinical trial management systems (CTMS) market is projected to grow from USD 2.17 billion in 2026 to USD 6.44 billion by 2034, exhibiting a CAGR of 14.56%.
• Immuno-oncology and Regenerative Biologics: While specific market sizes for OSRH's oral immunotherapies for cancer (e.g., VXM01 for glioblastoma and pancreatic cancer) and regenerative biologics (e.g., DRT-102 for spinal fusion, DRT-101 for osteoarthritis) are not precisely quantified in the available data, these areas fall under the broader biotechnology market. The biotechnology market in South Korea, where OSRH has a strategic focus, generated USD 25,642.9 million in 2023 and is expected to reach USD 81,627.0 million by 2030, growing at a CAGR of 18.3% from 2024 to 2030.
• Neurovascular Intervention Medical Device and Systems Distribution: In South Korea, the medical device sector generated 37.9 trillion won (approximately USD 31.6 billion) in sales in 2023.
• Non-invasive Glucose Monitoring Technology: OSRH's pending acquisition of Woori IO will add non-invasive glucose monitoring technology. The global continuous glucose monitoring (CGM) market is projected to be worth USD 47 billion by 2034.

Here are 3-5 expected drivers of future revenue growth for OSR Health (OSRH) over the next 2-3 years:

1. VXM01 Global Licensing Agreement and Milestone Payments: OSR Health recently secured an $815 million definitive exclusive license agreement with BCM Europe AG (BCME) for the worldwide development, commercialization, and out-licensing of VXM01. This oral immunotherapy, which is Phase-2b/3 ready for glioblastoma multiforme (GBM) and pancreatic cancer, is expected to generate significant milestone payments for OSR Health, with at least $15 million in cash anticipated within six months under a specialty-financed structure.
2. Commercialization of Non-Invasive Glucose Monitoring (Woori IO): The acquisition of Woori IO and its non-invasive glucose monitoring technology is a key driver. This technology aims to eliminate the need for traditional finger-prick testing and has received non-dilutive funding from Samsung Electronics. As the platform advances toward regulatory approval in Korea and potentially other markets, it represents a new and significant revenue stream for OSR Health.
3. Expansion of Fourth-Party Logistics (4PL) Business (RM Communications): OSR Health's subsidiary, RM Communications (RMC), is expanding its profitable medical device distribution into a 4th-party logistics (4PL) model. This expansion involves offering comprehensive import licensing, regulatory services, and logistics consolidation for hospitals and medical device manufacturers, particularly in South Korea. This strategic shift is expected to enhance RMC's market position and drive revenue growth through increased service offerings and market share.
4. Development and Commercialization of Biologics for Degenerative Diseases (Darnatein): The continued development and eventual commercialization of Darnatein's AI-designed biologics, DRT-101 and DRT-102, for osteoarthritis and spinal fusion, respectively, represent another future revenue growth driver. While currently in early stages without reported sales, the promising early data suggesting superior bone and cartilage regeneration potential could lead to substantial revenue if successful clinical trials and market introductions are achieved.

Share Issuance

• OSR Holdings experienced substantial shareholder dilution, with shares outstanding increasing by 72% in the past year (as of March 2025) and by 607.51% over the last year (as of June 2026).
• In February 2025, the company entered into an Equity Line of Credit (ELOC) agreement for potential financing of up to $80 million, issuing 1,692,500 shares and raising gross proceeds of $1,259,753 by December 31, 2025.
• OSR Holdings is seeking shareholder approval to raise its equity plan to 8.0 million shares and for potential issuances of common stock exceeding 20% of outstanding shares under its 2025 Omnibus Incentive Plan (as of May 2026).

Inbound Investments

• OSR Holdings entered into an Equity Line of Credit (ELOC) agreement in February 2025, providing access to up to $80 million in financing.
• In April 2026, OSR Holdings executed a definitive global exclusive license agreement with BCM Europe AG for VXM01, which includes potential milestone obligations of up to $815 million.
• Joint Protein Central, Inc. reported beneficial ownership of 2,603,759 shares, representing 7.9% of OSR Holdings' common stock, as of April 22, 2026.

Outbound Investments

• OSR Holdings acquired the full VXM01 Intellectual Property Portfolio in a $30 million transaction, announced in May 2026.
• The company entered into a Share Exchange Agreement to acquire all outstanding shares of Woori IO Co., Ltd., making Woori IO a wholly owned subsidiary.

Capital Expenditures

• Capital expenditures for the last twelve months (ending around May/June 2026) amounted to approximately -$176,385.